Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis.
Past and present asbestos use will reflect in increasing numbers of mesothelioma cases in the next decades, diagnosed at a late stage and with a dismal prognosis. This stresses the need for early detection tools, which could improve patients' survival. Recently, breath analysis as a noninvasive and fast diagnostic tool has found its way into biomedical research. High-throughput breathomics uses spectrometric, chromatographic, and sensor techniques to diagnose asbestos-related pulmonary diseases based upon volatile organic compounds (VOC) in breath. This article reviews the state-of-the-art available breath analyzing techniques and provides the insight in the current use of VOCs as early diagnostic or prognostic biomarkers of mesothelioma to stimulate further research in this field. Cancer Epidemiol Biomarkers Prev; 23(6); 898-908. ©2014 AACR.
Authors' Affiliations: Department of Respiratory Medicine, Ghent University Hospital, Ghent; Department of Internal Medicine, Ghent University, Ghent; Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven; and Thoracic Oncology/MOCA, Antwerp University Hospital, Edegem, BelgiumAuthors' Affiliations: Department of Respiratory Medicine, Ghent University Hospital, Ghent; Department of Internal Medicine, Ghent University, Ghent; Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven; and Thoracic Oncology/MOCA, Antwerp University Hospital, Edegem, Belgium kevin.lamote@uzgent.be.
Kevin
K
Lamote
Authors' Affiliations: Department of Respiratory Medicine, Ghent University Hospital, Ghent; Department of Internal Medicine, Ghent University, Ghent; Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven; and Thoracic Oncology/MOCA, Antwerp University Hospital, Edegem, Belgium.
Kristiaan
K
Nackaerts
Authors' Affiliations: Department of Respiratory Medicine, Ghent University Hospital, Ghent; Department of Internal Medicine, Ghent University, Ghent; Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven; and Thoracic Oncology/MOCA, Antwerp University Hospital, Edegem, BelgiumAuthors' Affiliations: Department of Respiratory Medicine, Ghent University Hospital, Ghent; Department of Internal Medicine, Ghent University, Ghent; Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven; and Thoracic Oncology/MOCA, Antwerp University Hospital, Edegem, Belgium.
Jan P
JP
van Meerbeeck
D001944:Breath Tests / Q000379:methods; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D008654:Mesothelioma / Q000175:diagnosis* / Q000378:metabolism; D000086002:Mesothelioma, Malignant; D011379:Prognosis